Norepinephrine Quinazolinone Imaging Agents for Cardiac Perfusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging technologies lack effective agents for early diagnosis of heart failure and for assessing perfusion and innervation mismatch in the heart, which are critical for managing cardiac conditions.
Innovation Solution
Development of compounds and compositions that serve as imaging agents, capable of imaging perfusion and innervation, and methods for synthesizing these agents to assess perfusion and innervation mismatch in the heart.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current imaging technologies are used, then existing imaging capabilities are maintained, but early diagnosis of heart failure and assessment of perfusion/innervation mismatch cannot be achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of imaging agents to include specific functional groups (e.g., norepinephrine derivatives with quinazolinone moieties) that enable detection of early heart failure and perfusion/innervation mismatch. The structural parameters of the imaging agent are changed to optimize binding affinity and imaging characteristics, thereby achieving early diagnosis capability that was not possible with conventional agents.
Solution Approach 2:
The patent employs composite materials by combining multiple functional components within the imaging agent molecule. The agents are composed of norepinephrine derivatives coupled with quinazolinone or related heterocyclic moieties, creating composite molecular structures that simultaneously provide neuroimaging capability and perfusion assessment functionality, enabling dual-purpose diagnostic applications.
2Adaptability or versatility
If no specialized imaging agents are developed, then existing imaging methods continue to be used, but perfusion and innervation mismatch cannot be assessed
Solution Approach 1:
The patent implements universality by designing imaging agents that can perform multiple diagnostic functions simultaneously. The norepinephrine derivative agents can assess both perfusion (blood flow) and innervation (nerve function) in cardiac tissue, providing versatile diagnostic capability from a single agent administration, thereby improving adaptability without requiring multiple separate imaging procedures.
Solution Approach 2:
The patent applies segmentation by dividing the imaging function into distinct molecular components within the agent structure. The norepinephrine portion targets adrenergic receptors for innervation assessment, while the coupled heterocyclic moiety provides perfusion imaging capability, allowing the complex diagnostic task to be segmented into detectable molecular functions.
Data Source
AI summary
The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.